3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case.

Intuitive Surgical (NASDAQ: ISRG) has built a leading position in robot-assisted surgery, and three Wall Street analysts see its shares reaching $500. Oppenheimer upgraded the stock to Outperform in August with a $500 price target. Meanwhile, Citigroup and Baird lowered their targets to $500 in July but kept their Buy and Outperform ratings.

As more hospitals adopt its technology, the company is finding new ways to accelerate growth. Here's why the bull case may have more room to run.

Image source: Getty Images.

Robotic surgery gives Intuitive Surgical a powerful growth engine

Intuitive Surgical's bull case is straightforward: it isn't just selling surgical robots; it's building a whole ecosystem that hospitals and surgeons can rely on for years. Its flagship da Vinci surgical system allows surgeons to perform minimally invasive procedures using robotic tools through a console.

But the bigger revenue driver is what happens after a hospital purchases a robot.

Intuitive can generate recurring revenue from instruments, accessories, and servicing as hospitals continue to use its systems. That creates a business model with both a sales component for equipment and an ongoing revenue stream from surgical procedures.

The company's next major opportunity comes from Intuitive's latest platform, da Vinci 5. The system builds on established technology with features such as improved imaging, enhanced computing capabilities, and tools to support surgical workflows. If it succeeds, da Vinci 5 could encourage new purchases, upgrades, and broader adoption across hospitals.

The new rollout is already underway. In the second quarter of 2026, Intuitive placed 246 da Vinci 5 systems, up from 180 in the previous year. That suggests that the new platform is already contributing to more overall sales.

But of course, the bull case doesn't depend entirely on selling new robots. As the installed base expands, Intuitive has more opportunities to generate recurring revenue from the tools and accessories used in procedures.

More procedures mean more recurring revenue

Beyond intelligent surgical robots, Intuitive also benefits when hospitals use its systems more frequently. Each additional procedure can create demand for accessories and related services. And so far, the trend has been encouraging. Compared with the same quarter last year, procedures done by surgeons using da Vinci systems grew 15%, while revenue from instruments and accessories climbed 18% to roughly $1.7 billion.

These figures demonstrate why Intuitive's business model is so compelling. The company doesn't need every dollar of growth to come from selling another robot. It can also grow by making greater use of the systems already installed in hospitals.

The opportunity extends beyond the U.S., too. Intuitive reported strong international procedure growth, supported by broader adoption across surgical specialties. Continued expansion into new markets could help the company reach hospitals and surgeons that have yet to adopt robot-assisted surgery.

On top of that, Intuitive's Ion platform adds another opportunity beyond da Vinci and surgical robotics. Ion provides robot-assisted bronchoscopy, which helps physicians perform biopsies on lung nodules that may be difficult to access using traditional techniques. That matters because finding lung cancer earlier can be important for treatment decisions. Ion gives Intuitive exposure to the broader push toward earlier diagnosis rather than focusing only on growth in surgical procedures.

Still, the bull case is not without risks. Some of these risks include slower procedure growth, limited hospital budgets, and stronger competition from other surgical robotics companies. But if the company successfully navigates these risks, the upside could be compelling.

Is Intuitive Surgical stock a buy at today's valuation?

A consensus among 31 Wall Street analysts rates Intuitive Surgical a Strong Buy, with target prices indicating potential upside of between 12% and 60% over the next 12 months. However, the biggest challenge today is valuation. The stock trades at a price-to-earnings ratio (P/E) of about 49, which leaves less room for disappointment if procedure growth slows or new system sales fall short of expectations.

Looking ahead, third-quarter results, expected on or around Oct. 20, will show whether procedure growth and da Vinci 5 placements are holding up. Still, for investors who believe robot-assisted surgery will only become more common, today's stock price might make sense. If Intuitive Surgical accelerates earnings growth and exceeds those high expectations, the stock has a realistic path to $500.

Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends the following options: long January 2028 $520 calls on Intuitive Surgical and short January 2028 $530 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.